Singapore Institute of Advanced Medicine Holdings Past Earnings Performance
Past criteria checks 0/6
Singapore Institute of Advanced Medicine Holdings's earnings have been declining at an average annual rate of -31%, while the Healthcare industry saw earnings growing at 15.1% annually. Revenues have been growing at an average rate of 17.6% per year.
Key information
-31.0%
Earnings growth rate
-20.4%
EPS growth rate
| Healthcare Industry Growth | 9.7% |
| Revenue growth rate | 17.6% |
| Return on equity | -42.2% |
| Net Margin | -116.8% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Singapore Institute of Advanced Medicine Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 16 | -19 | 12 | 0 |
| 30 Jun 22 | 14 | -14 | 12 | 0 |
| 30 Jun 21 | 13 | -9 | 9 | 0 |
Quality Earnings: 9G2 is currently unprofitable.
Growing Profit Margin: 9G2 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 9G2's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare 9G2's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 9G2 is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (-2%).
Return on Equity
High ROE: 9G2 has a negative Return on Equity (-42.21%), as it is currently unprofitable.